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Abstract: Irreversible electroporation (IRE) is a relatively new technique for tumor ablation. It has shown promising 
results in difficult cases where surgery is not recommended and delicate anatomic structures are present near or 
within the tumor. Currently, liver cancer is one of the most common targets for IRE treatment. Pre-operative and 
post-operative imaging has a key role in IRE procedures and research studies. Although ultrasound is usually the 
first choice, especially for intra-operative guidance, magnetic resonance imaging (MRI) plays an important role in
the visualization and characterization of tumor before and after IRE in clinical and preclinical studies. However, the
appearance of liver lesions after IRE with different MRI sequences has never been systematically investigated, and 
the most common practice is to limit the acquisition protocol to only contrast-enhanced T1-weighted images. In 
this work, the role of MRI in clinical and preclinical assessment of hepatic tumors treated with IRE is reviewed and 
discussed.
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Introduction
Electroporation is the use of an electric field to
create nanopores in cell membranes, thus 
making them more permeable. This permeabili-
zation can be temporary or permanent depend-
ing on the amplitude and duration of the applied 
electric field, and the corresponding proce- 
dures are consequently called reversible (RE)
and irreversible (IRE) electroporation. Although
IRE has been studied for many years, it has 
been applied to cancer treatment only relative- 
ly recently [1]. Many studies have demonstrat- 
ed the feasibility and safety of IRE [2-7]. 
Compared to other techniques for tumor abla- 
tion, such as cryosurgery, focused ultrasound, 
interstitial laser coagulation and radiofrequen-
cy ablation, IRE has the advantage that the cre-
ated ablation zone is well demarcated; its 
extent can be accurately controlled; and it can 
be obtained with an easy and short procedure. 
It also avoids the adverse effects related to the 
use of high temperatures. In particular, it pre-
serves vital structures within and in proximity to 
the treated area, such as blood vessels [8]. IRE 
is increasingly being used for tumor treatment 
in patients who are not surgical candidates. The 
liver is an ideal target organ, due to its sensitiv-
ity to thermal damage and the presence of deli-
cate anatomic structures such as hepatic ves- 
sels and bile ducts [9]. The preservation of 
these structures after IRE has been confirmed 
by many studies by many studies [10-12].
Imaging techniques have a key role in IRE stud-
ies. Pre-operatively, images are acquired to 
characterize the tumor, in particular its location 
and dimension, to plan the treatment in terms
of the number and arrangement of electrodes
and the parameters of the electric pulses. 
Imaging is also used during the intervention to
guide electrode placement. In the immediate
post-operative period imaging is used to verify 
that ablation is performed as planned and to 
check for the occurrence of acute complica- 
tions. At later time points, imaging is essential
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for monitoring of the treated area to better 
understand the evolution of the lesion and the
involved biological processes, and in particular
to verify the response to treatment and possi- 
bly to plan further therapeutic interventions.
Ultrasound (US) is the most frequently used 
modality and the only one that can be applied 
during the treatment with IRE. Computed
Tomography (CT) is commonly used pre- and
post therapy due to its availability. However, 
magnetic resonance imaging (MRI) scanning 
has distinct advantages over US and CT due to 
its excellent soft tissue contrast and its ability 
to provide dynamic contrast enhancement 
data.
In the following sections, published clinical and
preclinical studies applying MRI before and/or 
after liver IRE are reviewed.
Clinical studies
The primary purpose of most of the clinical 
studies on liver IRE that have included MRI 
examinations is to assess the feasibility and
the effects of the treatment, rather than to
evaluate the performance of MRI sequences in 
the visualization of biophysical changes after 
IRE. The only goal of imaging of the treated 
area is to search for the presence of residual 
viable tumor and to inspect the surrounding 
area for complications, in particular when the 
ablated tumor is close to important structures 
such as vessels or bile ducts.
The acquisition protocol for tumor assessment 
before or after IRE typically includes contrast- 
enhanced T1-weighted MRI that is performed 
after the injection of a gadolinium-based con-
trast agent. The time between the contrast
injection and scanning has to be taken into
account because contrast enhancement has 
different phases (hepatic arterial, portal
venous, equilibrium, delayed, and hepatobiliary
excretion [13]), so the right timing has to be 
chosen to focus on specific structures and 
tumor. For example, when assessing hepatocel- 
lular carcinoma, arterial and venous phases
are mandatory. In colorectal cancer liver metas-
tases, arterial phase is less important.
Sometimes T2-weighted and diffusion-weight- 
ed images are acquired in liver IRE patients, 
but they are less common than contrast-
enhanced T1-weighted imaging as their roles in
the assessment of response to IRE therapy is 
not widely established. Quantitative MRI analy- 
ses have been performed only sporadically. 
See Table 1 for a summary of the clinical stud- 
ies, including a brief description of the acquisi- 
tion protocol and of the quantitative analyses 
that were performed, if any.
MRI assessment of response to treatment
The main purpose of clinical studies in patients 
with liver IRE is to assess response to treat- 
ment, usually by evaluating residual contrast 
enhancement in post-operative images.
One of the first clinical studies on liver IRE that 
included MRI is a retrospective study of 28
patients with a total of 65 liver tumors [14].
Contrast-enhanced CT and/or MRI were 
acquired preoperatively to evaluate the size
and location of tumors; IRE electrodes were
placed with US or CT guidance to include a 1-
cm margin around the tumor in the ablation 
zone. The imaging protocol was repeated in the 
immediate post-operative period, and 1, 3 and 
6 months after treatment. One tumor had per- 
sistent disease, defined as residual contrast
enhancement in the tumor area at the first fol-
low-up imaging session, whereas in 3 cases 
there were local recurrences, defined as 
enhanced tumors within 1 cm of the ablation
zone that were observed 2 to 8 months after
IRE.
In a subsequent study, 44 patients (20 colorec- 
tal liver metastasis, 14 hepatocellular cancer, 
and 10 other metastases) undergoing IRE for 
hepatic tumors were evaluated [15]. Based on 
preoperative CT, tumor dimensions were mea- 
sured and the treatment was planned. Post-
operative CT or MRI were acquired shortly after
the treatment and at 3-month intervals after- 
wards. Images were reviewed to identify the 
presence of residual viable tumor and the local 
recurrence-free survival rate was measured. 
The rate was 97.4% at 3 months, 94.6% at 6 
months, and 59.5% at 12 months. Interestingly, 
when this analysis was repeated considering 
only lesions smaller than 3 cm, the local recur- 
rence-free survival increased dramatically: 
100% at 3 and 6 months and 98% at 12 
months.
In a case report on a patient with hepatocellu-
lar carcinoma (HCC) adjacent to a transjugular
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Table 1. Summary of liver IRE clinical studies including MRI acquisitions
Study Primary aim MRI sequences Quantitative measures
Kingham et 
al., 2012 [14]
To evaluate recurrence and complica- 
tions after liver IRE
Not specified Tumor size
Distance to the closest major 
hepatic vein or portal pedicle 
Area of the ablation zone
Mannelli et 
al., 2013 [17]
To report MRI appearance of a liver 
metastasis after IRE
Unenhanced and contrast-enhanced T1-weighted None
Diffusion-weighted (details not specified)
Cannon et al., 
2013 [15]
To evaluate clinical safety and efficacy Not specified Tumor size
of IRE on hepatic tumors
Niessen et al., 
2013 [16]
To report IRE effects on a HCC lesion T1-weighted None
Diffusion-weighted (details not specified)
Narayanan et 
al., 2014 [20]
To evaluate IRE effects on vessels in 
close proximity to the ablation zone
Contrast-enhanced (details not specified) Distance from tumor to
vessels
Granata et al., 
2015 [13]





T1-weighted GRE in 5 different phases after contrast ad- 
ministration (hepatic arterial, portal venous, equilibrium, 
delayed, hepatobiliary excretion)
Area of the ablation zone 




To evaluate alterations in venous 
structures adjacent to the ablation 
zone after IRE of malignant hepatic 
tumors
Not specified Tumor diameter
Distance from IRE needle to 
closest vessel
Vessel diameter
Granata et al., 
2016 [18]




To compare the diagnostic accuracy 
of MRI, CT and US in the evaluation of 
the ablation area after IRE of HCC
To assess MRI findings after IRE of 
HCC
To evaluate biliary complications after 




T1-weighted GRE in 5 different phases after contrast ad- 
ministration (hepatic arterial, portal venous, equilibrium, 
delayed, hepatobiliary excretion)
T2-weighted TSE
T1-weighted GRE pre-contrast and in 3 phases after 
contrast administration (hepatic arterial, portal venous 
and delayed)




Apparent Diffusion Coef- 
ficient





Abbreviations: TSE = Turbo Spin Echo, GRE = Gradient Echo, FSE = Fast Spin Echo.
intrahepatic portosystemic shunt stent-graft 
[16], imaging was performed, including pre-
operative contrast-enhanced US and MRI,
intra-operative CT-fluoroscopy and US, post-
operative contrast-enhanced US, CT and MRI 
24 h and 8 weeks after IRE. Focusing on MRI, a
T1-weighted sequence in the hepatobiliary
phase and a diffusion-weighted sequence were 
acquired. In the pre-operative scans, the lesion
was hypointense in T1-weighted and hyperin-
tense on diffusion-weighted images. The post- 
operative scans showed a sharp demarcation 
of the hypointense ablation zone in the T1- 
weighted images and loss of the hyperintensity
in the diffusion-weighted images, confirming
the complete success of the ablation pro- 
cedure.
In another case report on a liver metastasis
[17], MRI was performed 1 day after IRE. A
large area of ablation was evident at the site of 
the metastasis (Figure 1A-C), which presented 
no contrast enhancement and was thus pre-
sumed to be necrotic/apoptotic. It was sur-
rounded by a rim of contrast enhancement 
(Figure 1D, 1E) and hyperintensity in the diffu-
sion-weighted images (Figure 1F). Images ac-
quired 30 days later showed complete radio- 
logical liver parenchyma regeneration (Figure 
1G).
Another group followed 20 patients undergoing 
IRE for HCC [13]. Contrast-enhanced US and 
MRI were acquired 5 days before and 1 month
after IRE. The MRI acquisition protocol included
T1-weighted, T2-weighted and diffusion-weight-
ed imaging; in particular, dynamic T1-weighted 
images were acquired in 5 different phases: 
hepatic arterial, portal venous, equilibrium, 
delayed, and hepatobiliary excretion. At post- 
operative examination, 22 out of the 24 treated 
lesions showed complete response; the remain- 
ing two showed partial response, with areas of 
contrast enhancement during the arterial 
phase and portal phase washout. All the abla- 
tion zones appeared non-homogeneous hypoin-
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Figure 1. MRI appearance of a liver metastasis before and after IRE. (A, B) Pre-operative MRI showing the metasta- 
sis as an hypointense area. (C-E) Post-treatment MRI before (C) and after (D, E) contrast injection. (F) Post-treatment 
diffusion-weighted MRI. (G) Images acquired 30 days after IRE. Reproduced with permission from [17].
tense in the T2-weighted images and with a 
hyperintense central core surrounded by a
hypointense rim in the T1-weighted images. The
residual tumors appeared as hypointense 
areas in T1-weighted and hyperintense areas in
T2-weighted images at the periphery of the
ablation zones. The diffusion-weighted signal
was hyperintense at b = 800 s/mm2 in most of 
the cases, whereas in a few cases the lesions 
were not clearly visible at b = 0 s/mm2 and the 
signal was not detectable at b = 800 s/mm2. 
The size of the ablation areas was measured 
and it was 10% larger than at baseline imaging 
on average. Apparent diffusion coefficients 
were derived from diffusion-weighted images 
and measured in lesions. There was a trend
towards higher diffusion coefficients one month
after IRE with respect to baseline, although the 
difference was not statistically significant.
Data from the same patients were used to com- 
pare the diagnostic accuracy of contrast- 
enhanced US, CT and MRI 1, 3 and 6 months 
after IRE [18]. At the first time point, MRI and 
US showed complete response in 22 out of 24 
lesions and progressive disease in the other 
two, with a residual tumor diameter of approxi- 
mately 10 mm according to both modalities. On 
the other hand, all the treated areas appeared 
as necrotic on CT scans. At 3 months, MRI and 
US showed a very similar pattern compared to 
the scans at 1 month, with only a slight increase 
of the diameter of the two residual tumors mea-
sured using MRI (11 and 12 mm). CT showed 
23 necrotic areas and one residual viable tumor
with a diameter of 10 mm. At 6 months, all the
three modalities showed 22 necrotic areas and 
2 residual tumors, with diameters of 12 and 14 
mm measured using MRI, 11 and 12 mm using
US, and 10 and 10 mm using CT. The two resid-
ual tumors were treated again, and intra-opera- 
tive US confirmed the lesion dimensions mea- 
sured on MRI.
Finally, a recent retrospective study considered 
20 patients with HCC [19]. The MRI protocol,
including T2-weighted and dynamic contrast-
enhanced T1-weighted sequences, was repeat-
ed 1 and 30 days after IRE, and every 90 days 
thereafter. At one month, 18 out of 20 patients 
had complete response to treatment and the 
other two had partial responses. One day after 
IRE, the ablated lesions showed a central area
that was hyperintense in the T2-weighted and
T1-weighted images, surrounded by a rim that
was even more hyperintense in the T2-weighted 
images, hypointense on the unenhanced T1-
weighted images and hyperintense in the
enhanced T1-weighted images (Figure 2D-F). 
The size of the ablation zone and the periphery 
decreased over time, with the largest decrease 
occurring in the first 30 days. The T2-weighted 
signal tended to decrease over time. The
T1-weighted signal in the tumor tended to
increase and the signal in the periphery tended
to increase in unenhanced and decrease in
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Figure 2. Typical MRI appearance of HCC after IRE. (A, B) Baseline axial and coronal contrast-enhance T1-weighted 
MRI acquired in the arterial phase showing an HCC in the right hepatic lobe. (C) Post-IRE CT showing the electrodes. 
(D-F) Images acquired 24 hours after IRE, showing an ablation area that is hyperintense at T2-weighted MRI (D), 
slightly hyperintense with an hypointense margin at unenhanced T1-weighted MRI (E) and hypointense with hy- 
perintense margin at contrast-enhanced T1-weighted MRI during the arterial phase (F). (G-I) T2-weighted MRI (G), 
unenhanced (H) and contrast-enhanced (I) T1-weighted MRI acquired 30 days after IRE, showing similar signals but 
reduced dimensions with respect to the previous time point. (J-L) T2-weighted MRI (J), unenhanced (K) and contrast- 
enhanced (L) T1-weighted MRI acquired 120 days after IRE, showing a further reduction of the ablation zone and no 
contrast enhancement. Reproduced with permission from [19].
enhanced T1-weighted images (Figure 2G-L).
The authors speculated that the peripheral 
enhancing zone, resolving over time, could be a 
penumbra of reversible electroporation.
Assessment of complications after IRE
Another important aim of post-operative MRI in 
liver IRE clinical studies is the assessment of
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Figure 3. Portal vein narrowing in a case of colorectal cancer. A: Pre-interventional contrast-enhanced T1-weighted 
MRI shows a freely perfused right branch of the portal vein (thin arrow). B: 3 days after IRE, MRI shows a caliber re- 
duction of the right portal vein (thin arrow), encased by the ablation zone (thick arrows). C: 6 weeks after treatment, 
the lumen reduction of the right portal vein (thin arrow) has resolved. Reproduced from [21].
complications occurring to surrounding struc- 
tures after treatment.
In the study by Kingham et al. cited in the previ-
ous section [14], post-operative images were 
also reviewed to assess complications involv-
ing vessels included in the ablation zone. Major
hepatic veins and portal pedicles were within 1 
cm from tumors in 57% and 40% of the cases, 
respectively. All the structures were patent at
follow-up imaging, with the only exception being
one portal pedicle, in which post-operative 
imaging showed a thrombus.
More recently, Narayanan et al. [20] examined 
101 patients undergoing percutaneous IRE 
procedures for 129 lesions in different organs, 
with the great majority (78%) in the liver. Con-
trast-enhanced CT or MRI was acquired 1, 3, 6
and 12 months after treatment to evaluate 
caliber, patency, and flow defects of vessels in 
close proximity (within 1 cm) to the ablation 
zone. One hundred fifty-eight of these vessels
were identified, including 40 abutting and 10
encased by the tumor. Abnormal vascular
changes were only found in 7 cases, including 4 
thromboses of the portal veins and 3 cases of 
mild narrowing. No significant association was 
found between the presence of narrowing/
thrombosis at follow-up imaging and the dis-
tance from the treatment zone.
A similar study examined 43 patients with
venous structures within 1 cm from the abla-
tion zone after IRE of 84 hepatic lesions [21].
Contrast-enhanced CT or MRI was acquired 
during the portal venous phase before and
after each intervention. Fifty-five venous struc-
tures were found to be surrounded by the abla-
tion zone, 78 abutting the ablation zone and 58 
between 0.1 and 1 cm away from the ablation 
zone, for a total of 191 examined vessels.
Follow-up imaging was performed 1 to 3 days
after treatment and showed abnormal changes 
in 19 vessels, including 5 portal vein thrombo- 
ses and 14 cases of lumen narrowing (Figure 
3). Patients with subacute alterations were fol- 
lowed by further follow-up imaging (6 ± 4 
months later). Two out of the 5 thromboses 
resolved, 8 out of the 14 cases with vessel nar-
rowing also completely resolved and another
one partly resolved. In this study, significant
associations were found between post-IRE ves- 
sel alterations and the encasement of a vessel 
by the ablation zone, with the ablation zone 
being adjacent to a portal vein, or the usage of 
more than 3 IRE probes.
The same group examined 24 patients with bile 
ducts within 1 cm from the ablation zone after 
percutaneous IRE of 53 hepatic tumors [22]. 
Pre- and post-interventional T1-weighted MRI
was acquired 20 minutes after the injection of
hepatocyte-specific Gd contrast (during the 
hepatobiliary phase). Thirty-three bile ducts 
were found to be encased, 14 abutting and 8
within a radius of 0.1-1.0 cm of the ablation
zone, for a total of 55 bile ducts examined for
changes in caliber, patency, and leakage. MRI 
was performed 1-3 days after IRE, and it
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Table 2. Summary of liver IRE preclinical studies including MRI acquisitions
Study Primary aim MRI sequences Quantitative measures
Guo et al., 
2010 [25]
To observe tumor evolution after IRE T2-weighted TSE
T1-weighted TSE 
PD-weighted TSE
Maximum lesion diameter 
Lesion cross-sectional area
Lee et al., 
2010 [10]
To evaluate IRE effects on the healthy liver 
and their appearance at MRI
T1-weighted GRE None
(before contrast ad- 
ministration and in the 
hepatic arterial and 
portal venous phases)
Zhang et al., To test the possibility to detect IRE effects T1-weighted GRE Area of the ablation zone





Guo et al., To evaluate ablation zones measures in the T1-weighted GRE Area of the IRE ablation zone
2011 [24] healthy liver by different MRI sequences IR FLASH with multiple Area of the RE penumbra
inversion times
Zhang et al., To compare alterations shown by different T1-weighted GRE Signal-to-noise Ratio before
2014 [26] imaging modalities after IRE in liver tumors T2-weighted FSE and after IRE
Abbreviations: TSE = Turbo Spin Echo, PD = Proton Density, GRE = Gradient Echo, IR = Inversion Recovery, FLASH = Fast Low 
Angle Shot, FSE = Fast Spin Echo.
showed 15 alterations, including dilations in 3 
encased, 3 abutting and one distant bile ducts, 
and the narrowing of 8 encased bile ducts.
These patients were followed by further follow-
up imaging (7.2 ± 5.3 months later); only the 3 
cases of dilated bile ducts encased by the abla- 
tion zone persisted at this time.
Preclinical studies
Preclinical studies have a different approach 
with respect to clinical ones: here the interest 
is not only in the success of the ablation proce- 
dure but also in understanding the biological
events occurring in the treated area over time
and how they can be monitored by imaging
techniques. More attention is paid to the choice 
of acquisition protocol and to the attainment of 
quantitative measures (Table 2), validated by 
either histology or other techniques.
The difference with respect to clinical studies is 
also reflected in the type of target tissues in 
preclinical IRE studies. In preclinical animal 
studies, there is always an untreated group and 
often animals with no tumors are included; IRE 
can be performed also on the healthy liver to 
understand its effects, size of ablation zone,
and how tissue alterations appear in images
acquired with different modalities. These ch-
anges and their imaging manifestation are dis- 
cussed below.
Studies on the healthy liver
The earliest preclinical study on IRE of the 
healthy liver with MRI scans included 16 pigs
[10]. A total of 55 ablation zones were pro-
duced. The main imaging modality in this work 
was US, which was acquired during and imme- 
diately after the procedure, and again the next
day. Two days after IRE, 2 animals with 6 abla-
tion zones were imaged by CT and 2 different 
animals with 6 ablation zones were imaged by 
MRI. The MRI protocol included a dynamic con-
trast-enhanced T1-weighted sequence. The
ablation zones appeared as hypointense on
T1-weighted images, with a mildly enhancing
rim. This work demonstrated that ablation 
areas can be monitored by real-time US and
reliably assessed by contrast-enhanced CT or
MRI.
In another study [23], 18 healthy rats were 
divided into 3 groups undergoing liver IRE with 
different voltages (1000, 1500 and 2500 V). 
Proton density, T1- and T2-weighted MRI 
sequences were acquired before and immedi- 
ately after the treatment. Ablation areas 
appeared as hyperintense on T2-weighted and
hypointense on T1-weighted images compared
to pre-operative images. Regions of interest
were manually delineated in these ablation 
zones and their area was measured. The results
were compared with the areas anticipated by
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Figure 4. IRE effects on the healthy liver in rats. A: Finite-element modeling simulations showing the anticipated 
IRE zone (white area) and RE penumbra (colored zones) corresponding to the 3 different electrodes configurations. 
B: Post-IRE T1-weighted gradient-echo MRI. C: Post-IRE inversion recovery MRI adjusted to null the signal in the RE 
penumbra. D: Corresponding hematoxylin-eosin-stained histology slices. Reproduced with permission from [24].
finite element modeling and with those mea- 
sured on histologic slides stained with hema- 
toxylin-eosin. The 3 sets of measures showed a 
very good correlation, with larger areas for high- 
er voltage.
Finally, Guo et al. [24] performed liver IRE in 17 
healthy rats. The animals were divided into 4
groups: 3 underwent IRE with different param-
eters (voltage and electrode spacing) after the 
injection of a contrast agent, whereas the 
fourth had IRE and MRI with no injected con-
trast. The MRI acquisition protocol included a
T1-weighted gradient-echo sequence and an
inversion recovery (IR) sequence with different
inversion times that were expected to null the 
signal in the normal liver, in the ablation area or 
in the surrounding penumbra (area of revers-
ible electroporation). Lesions were uniformly
hyperintense in the gradient-echo images and
in the IR images with the inversion time nulling 
the signal in the normal liver. On IR images with
the inversion time expected to null the signal in 
the penumbra, a central hyperintense lesion 
was surrounded by a hypointense periphery 
(Figure 4). Using the different acquired images 
as visual references, regions of interest were 
drawn on areas of irreversible and reversible
electroporation. The areas measured on all the
sequences were well correlated with those 
derived from hematoxylin-eosin histology, with 
highest correlation provided by the penumbra-
nulling IR sequence, whereas the gradient-echo
and the normal liver-nulling IR sequences tend-
ed to overestimate the ablation area compared 
to histology.
Studies on liver tumors
The earliest MRI study of IRE in an animal 
model of liver tumors included 30 rats with 
HCC that were divided into 4 treated and 2 con- 
trol groups with different sacrifice times [25]. 
The MRI protocol included proton density,
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Figure 5. Comparison of MRI and histology in rats with HCC, untreated or 
treated with IRE. Top panel: untreated rat; bottom panel: IRE-treated rat. Left:
axial and coronal baseline T2-weighted images, acquired shortly before IRE
for the treated rats. Center: axial and coronal T2-weighted images acquired
15 days later. Right: corresponding ematoxylin-eosin-stained histology slides.
Reproduced with permission from [25].
ered (healthy or tumor), the 
procedure that was conduct- 
ed (IRE, IRE with vessel liga- 
tion or no treatment) and the 
imaging modality used to fol- 
low them (US, CT or MRI). 
The MRI protocol included a
T1-weighted and a T2-wei-
ghted sequence with no 
injection of contrast agent. 
The normal liver tissue and 
the tumor were hypointense 
in the T1-weighted and hy-
perintense in the T2-wei-
ghted images after IRE. The 
signal-to-noise ratio in the 
normal liver decreased sig- 
nificantly after IRE on T1-wei-
ghted images and increased
significantly on T2-weighted 
images, whereas in tumors 
no significant change was 
observed following IRE. The 
tumors treated after hepatic 
vessel ligation showed no 
MRI signal change after IRE, 
suggesting that early signal
changes are likely the result
of local fluid accumulation 
owing to transient permeabi-
lization of blood vessels,
with subsequent fluid build- 
up after rapid extravasation
into the treated tissue zones.
Conclusion and future per- 
spectives
MRI is still not the primary 
choice for imaging in liver
T1-weighted and T2-weighted sequences and
was performed at baseline and before eutha- 
nizing each animal. Tumors appeared as con-
sistently hyperintense in the T2-weighted imag-
es, hypointense in the T1-weighted images and 
typically isointense in the proton density imag- 
es (Figure 5). The size of the lesions was mea- 
sured as the maximum diameter and the cross-
sectional area. Both measures decreased in
the treated tumors (-32% and -52% on average, 
respectively) and considerably increased in all 
the untreated tumors (+110% and +286% on 
average, respectively).
In another study [26] 48 rats were divided into 
8 groups according to the type of tissue consid-
IRE studies. However, the interesting prelimi-
nary results provided by several studies and 
the potential superiority in assessment of 
tumor response to IRE compared to other imag-
ing techniques should foster a wider applica-
tion of MRI. The feasibility and utility of 
advanced and quantitative techniques such as 
diffusion and perfusion MRI which are sensitive 
to microstructural and vascular alteration
remain to be fully studied. This could improve
the understanding of the biophysical processes 
involved in the tissue response to IRE and may 
provide functional biomarkers of treatment effi- 
cacy that are more reliable than T1-weighted, 
T2-weighted, and contrast enhanced MRI 
approaches.
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